medigraphic.com
Órgano Oficial del Hospital Ángeles Health System

2026, Number 3

<< Back Next >>

Acta Med 2026; 24 (3)

Osseointegration of grafts and bioactive bone substitutes in the management of bone defects or losses in pediatric patients

Zavala LND, Mora RFG, García BP, Domínguez GRC, Hernández RAK, Braña RK, Muñoz HBM, Romero GED, Peña MMF

Language: Spanish
References: 36
Page: 215-221
PDF size: 1029.65 Kb.


ABSTRACT

Introduction: bone defects are defined as the lack of a bone segment; tumor and traumatic etiology represent the main cause in pediatric patients. Allografts continue to be the most used treatment, however there are bioactive molecules that promise lower rates of infection, rejection or pseudoarthrosis. Objective: to evaluate the osseointegration of allografts and bioactive bone substitutes (SOB) in the management of pediatric bone defects. Material and methods: a descriptive, retrospective study was carried out analyzing 59 patients with bone defects treated with the placement of allograft or bioactive glass from January 1, 2013 to January 1, 2024, measuring osseointegration based on the ISOLS (International Symposium on Limb Salvage) scale at 6 months post-surgery. Results: 59 patients were included, 59% male vs 41% female, mean age of 12.92 years. Etiology 68% tumor, 20% pseudoarthrosis, 12% traumatic. Predominantly affecting tibia (36%) and femur (31%), using allografts (76.7%) and SOB (24%), ISOLS excellent (78%) or good (12%), the association between type of graft and the resulting ISOLS did not show a statistically significant difference (p = 0.666). Conclusion: both types of grafts promise favorable results, however the difference in the number of patients treated with allografts vs SOB does not allow us to establish a therapeutic advantage of one over the other.


REFERENCES

  1. Hernández-Flores C, Delgado A, Domínguez-Hernández VM.Evaluación biomecánica de un modelo de defecto óseo en tibia derata. Rev Mex Ing Biomed. 2011; 32 (1): 12-19.

  2. Nauth A, Schemitsch E, Norris B, Nollin Z, Watson JT. Critical-sizebone defects: is there a consensus for diagnosis and treatment? JOrthop Trauma. 2018; 32 Suppl 1: S7-11.

  3. Obremskey W, Molina C, Collinge C et al. Current practice in themanagement of open fractures among orthopaedic trauma surgeons.Part B: management of segmental long bone defects. A survey ofOrthopaedic Trauma Association members. J Orthop Trauma. 2014;28 (8): e203-207.

  4. Vejarano-Solano JC, Ruiz-Semba CF, Ganoza-Arróspide CJ, Hurtado-Fernández JE. Reconstrucción de defectos óseos segmentariospostraumáticos mediante técnica de inducción de membrana. RevMed Hered. 2015; 26 (2): 76-86.

  5. Keating JF, Simpson AHRW, Robinson CM. The management offractures with bone loss. J Bone Joint Surg Br. 2005; 87 (2): 142-150.

  6. Hope PG, Cole WG. Open fractures of the tibia in children. J BoneJoint Surg Br. 1992; 74 (4): 546-553.

  7. Buckley SL, Gotschall C, Robertson W Jr, Sturm P, Tosi L, ThomasM et al. The relationships of skeletal injuries with trauma score,injury severity score, length of hospital stay, hospital charges, andmortality in children admitted to a regional pediatric trauma center.J Pediatr Orthop. 1994; 14 (4): 449-453. doi: 10.1097/01241398-199407000-00005.

  8. Sales de Gauzy J, Fitoussi F, Jouve JL, Karger C, Badina A, MasqueletAC. Traumatic diaphyseal bone defects in children. Orthop TraumatolSurg Res. 2012; 98 (2): 220-226.

  9. Gouron R, Deroussen F, Plancq MC, Collet LM. Bone defectreconstruction in children using the induced membrane technique:a series of 14 cases. Orthop Traumatol Surg Res. 2013; 99 (7): 837-843.

  10. Granel H, Bossard C, Nucke L et al. Optimized bioactive glass: thequest for the bony graft. Adv Healthc Mater. 2019; 8 (11): e1801542.

  11. Cueva del CJF, Valdés-Gutiérrez GA, Elizondo-Vázquez F et al.Tratamiento de pérdidas óseas, pseudoartrosis, artrodesis y tumoresóseos benignos con un xenoimplante mexicano (estudio clínico). CirCir. 2009; 77 (4): 287-291.

  12. Baldwin P, Li DJ, Auston DA, Mir HS, Yoon RS, Koval KJ. Autograft,allograft, and bone graft substitutes: clinical evidence and indicationsfor use in the setting of orthopaedic trauma surgery. J Orthop Trauma.2019; 33 (4): 203-213.

  13. García-Gareta E, Coathup MJ, Blunn GW. Osteoinduction of bonegrafting materials for bone repair and regeneration. Bone. 2015; 81:112-121.

  14. Shibuya N, Jupiter DC. Bone graft substitute: allograft and xenograft.Clin Podiatr Med Surg. 2015; 32 (1): 21-34.

  15. Wopenka B, Pasteris JD. A mineralogical perspective on the apatitein bone. Materials Science and Engineering. 2005; C 25 (2): 131-143.

  16. Mouriño V, Cattalini JP, Roether JA, Dubey P, Roy I, Boccaccini AR.Composite polymer-bioceramic scaffolds with drug delivery capabilityfor bone tissue engineering. Expert Opin Drug Deliv. 2013; 10 (10):1353-1365.

  17. Garg T, Singh O, Arora S, Murthy R. Scaffold: a novel carrier for celland drug delivery. Crit Rev Ther Drug Carrier Syst. 2012; 29 (1): 1-63.

  18. Albareda J, Sueiro-Fernández J, Zamora RJM. Injertos óseos versussustitutos óseos. ResearchGate. 2011.

  19. Martínez CA, Ozols A. Biomateriales utilizados en cirugía ortopédicacomo sustitutos del tejido óseo. Rev Asoc Argent Ortop Traumatol.

  20. 2012; 77 (2): 140-46.20. Heikkila JT, Kukkonen J, Aho AJ, Moisander S, Kyyrönen T, MattilaK. Bioactive glass granules: a suitable bone substitute material in theoperative treatment of depressed lateral tibial plateau fractures: aprospective, randomized 1-year follow-up study. J Mater Sci MaterMed. 2011; 22 (4): 1073-1080.

  21. Lindfors NC, Koski I, Heikkila JT, Mattila K, Aho AJ. A prospectiverandomized 14-year follow-up study of bioactive glass andautogenous bone as bone graft substitutes in benign bone tumors. JBiomed Mater Res B Appl Biomater. 2010; 94 (1): 157-164.

  22. Kargozar S, Baino F, Hamzehlou S, Hill RG, Mozafari M. Bioactiveglasses: sprouting angiogenesis in tissue engineering. TrendsBiotechnol. 2018; 36 (4): 430-444.

  23. Kargozar S, Montazerian M, Hamzehlou S, Kim HW, Baino F.Mesoporous bioactive glasses: promising platforms for antibacterialstrategies. Acta Biomater. 2018; 81: 1-19.

  24. Rodríguez-Rodríguez EI, Taura-Suárez L. Tumores óseos en edadpediátrica. AMC. 2019; 23 (5): 681-693.

  25. Mora RFG, Bustamante TBB, Mejía RLC, et al. Frecuencia de tumoresóseos benignos en niños. Rev Esp Med Quir. 2012; 17 (3): 179-185.

  26. Plaza D, Sastre A, García-Miguel P. Tumores óseos. An Pediatr Contin.2008; 6 (5): 266-275.

  27. Brito RA, Martínez SI, Torres MA, et al. Fracturas con pérdida óseasegmentaria en niños. Reporte de dos casos tratados con injertocorticoesponjoso autólogo. Acta Ortop Mex. 2006; 20 (6): 289-293.

  28. Gentile L, Iglesias SL, Lobos Centeno E, Vanoli F, Allende Nores CA.Defectos óseos diafisarios postraumáticos en la extremidad superiorde niños. Rev Asoc Argent Ortop Traumatol. 2017; 82 (4): 277-293.

  29. López-Martínez JJ, García-Sandoval PP, Fernández-Hernández JAet al. Funcionalidad y osteointegración de los aloinjertos óseos enosteosarcomas de huesos largos. Acta Ortop Mex. 2012; 26 (1): 30-34.

  30. Silva AFS, Criollo PFS. Aloinjerto óseo estructural en cirugía de salvamentode extremidades. Revisión teórica. Quito. 2021; 3 (1): 46-61.

  31. Aponte-Tinao L, Ayerza MA, Muscolo DL, Farfalli GL. Survival,recurrence, and function after epiphyseal preservation and allograftreconstruction in osteosarcoma of the knee. Clin Orthop Relat Res.2015; 473 (5): 1789-1796.

  32. Jorge FD, Varaona JM, Basso M. Uso de aloinjerto estructural einfecciones posquirúrgicas. Rev Asoc Argent Ortop Traumatol. 2022;87 (1): 23-33.

  33. Uzcátegui J, Gabaldón L, Rivas A, Brito M, Cosse J. Reconstrucción delhúmero con aloinjerto masivo tras resección en bloque por sarcomade Ewing. Evolución a largo plazo. A propósito de un caso. RevistaVenezolana de Cirugía Ortopédica y Traumatología. 2016; 48 (1).

  34. Haugen HJ, Lyngstadaas SP, Rossi F, Perale G. Bone grafts: which isthe ideal biomaterial? J Clin Periodontol. 2019; 46 Suppl 21: 92-102.doi: 10.1111/jcpe.13058.

  35. Dinopoulos H, Dimitriou R, Giannoudis PV. Bone graft substitutes:what are the options? Surgeon. 2012; 10 (4): 230-209.

  36. Pelissier P, Masquelet AC, Bareille R, Pelissier SM, Amedee J.Induced membranes secrete growth factors including vascular andosteoinductive factors and could stimulate bone regeneration.J Orthop Res. 2004; 22 (1): 73-79. doi: 10.1016/S0736-0266(03)00165-7.




2020     |     www.medigraphic.com